Patents by Inventor Marc W. Andersen
Marc W. Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230372299Abstract: The present disclosure provides formulations of an HGF/SF mimetic, terevalefim, as well as methods of preparing and using the formulations. The present disclosure also provides methods of synthesizing terevalefim.Type: ApplicationFiled: October 13, 2021Publication date: November 23, 2023Inventors: David Howard Upchurch, An-Hu Li, Weizhong Cai, Marc W. Andersen, Khawla Abdullah Abu-Izza
-
Publication number: 20230312561Abstract: The present disclosure provides crystalline solid forms of an antifibrotic agent, pharmaceutical compositions comprising the same, and methods of use thereof.Type: ApplicationFiled: June 30, 2021Publication date: October 5, 2023Inventors: Marc W. Andersen, Khawla Abdullah Abu-Izza
-
Patent number: 11634377Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: GrantFiled: January 27, 2021Date of Patent: April 25, 2023Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. Londesbrough, Marc W. Andersen
-
Publication number: 20210147335Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: ApplicationFiled: January 27, 2021Publication date: May 20, 2021Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. LONDESBROUGH, Marc W. ANDERSEN
-
Patent number: 10961273Abstract: Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified amino acid residues, which increases the efficiency of the synthetic process and the purity of the peptide product generated.Type: GrantFiled: August 9, 2017Date of Patent: March 30, 2021Assignee: Stealth Biotherapeutics Corp.Inventors: Scott M. Duncan, Jan Oudenes, Marc W. Andersen
-
Patent number: 10947183Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: GrantFiled: June 4, 2019Date of Patent: March 16, 2021Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. Londesbrough, Marc W. Andersen
-
Publication number: 20210040149Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: ApplicationFiled: March 13, 2020Publication date: February 11, 2021Applicant: Stealth BioTherapeutics CorpInventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
-
Publication number: 20190284124Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: ApplicationFiled: June 4, 2019Publication date: September 19, 2019Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. LONDESBROUGH, Marc W. ANDERSEN
-
Patent number: 10351510Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: GrantFiled: January 31, 2018Date of Patent: July 16, 2019Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. Londesbrough, Marc W. Andersen
-
Patent number: 10351509Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: GrantFiled: December 20, 2016Date of Patent: July 16, 2019Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. Londesbrough, Marc W. Andersen
-
Publication number: 20190202861Abstract: Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified amino acid residues, which increases the efficiency of the synthetic process and the purity of the peptide product generated.Type: ApplicationFiled: August 9, 2017Publication date: July 4, 2019Inventors: Scott M. Duncan, Jan Oudenes, Marc W. Andersen
-
Patent number: 10188693Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.Type: GrantFiled: July 31, 2013Date of Patent: January 29, 2019Assignee: Stealth Biotherapeutics CorpInventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
-
Publication number: 20180362579Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: ApplicationFiled: January 9, 2018Publication date: December 20, 2018Inventors: D. Travis WILSON, Marc W. ANDERSEN, Elizabeth MEAD
-
Publication number: 20180339012Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.Type: ApplicationFiled: December 20, 2017Publication date: November 29, 2018Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
-
Publication number: 20180148403Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: ApplicationFiled: January 31, 2018Publication date: May 31, 2018Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. LONDESBROUGH, Marc W. ANDERSEN
-
Publication number: 20170174613Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.Type: ApplicationFiled: December 20, 2016Publication date: June 22, 2017Applicant: ZOGENIX INTERNATIONAL LIMITEDInventors: Derek J. LONDESBROUGH, Marc W. ANDERSEN
-
Publication number: 20150157685Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.Type: ApplicationFiled: July 31, 2013Publication date: June 11, 2015Applicant: Stealth Peptides International, Inc.Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
-
Publication number: 20140294796Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.Type: ApplicationFiled: December 5, 2012Publication date: October 2, 2014Inventors: D. Travis Wilson, Marc W. Andersen, Elizabeth Mead
-
Publication number: 20100256229Abstract: The present invention is directed to compositions, methods of use, and processes for the synthesis related to 3-((S)-1-(dimethylamino)ethyl)phenyl methyl-((R)-1-phenylpropan-2 yl)carbamate, and its pharmaceutically acceptable salt forms, including the hydrogen fumarate salt. The present invention also relates to a novel form polymorph of 3-((S)-1-(dimethylamino)ethyl)phenylmethyl-((R)-1-phenylpropan-2 yl)carbamate, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.Type: ApplicationFiled: April 2, 2010Publication date: October 7, 2010Applicant: Colucid Pharmaceuticals, Inc.Inventors: Shoucheng Du, Marc W. Andersen, Daniel Coughlin, Alexander Kolchinski
-
Patent number: 6455507Abstract: Benzimidazole derivatives useful for treating or preventing viral infections such as those caused by herpes viruses or in the treatment of restenosis following surgical techniques. Methods of preparing these benzimidazole derivatives and pharmaceutical compositions containing them are described.Type: GrantFiled: March 17, 2000Date of Patent: September 24, 2002Assignee: SmithKline Beecham CorporationInventors: John Charles Drach, Leroy B. Townsend, Frank Leslie Boyd, Jr., Stanley Dawes Chamberlain, Susan Mary Daluge, David Norman Deaton, Marc W. Andersen, George Andrew Freeman